Antibiotics

The broad-spectrum investigational antibiotic has been developed for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Superbugs resistant to colistin – a last-resort antibiotic – may have a new foe in octapeptins, antibiotics discovered decades ago that recently have been found to be effective against multidrug-resistant gram-negative bacteria.

The Cystic Fibrosis Foundation has awarded Motif Bio with $120,000 that will fund in vitro testing for the development of iclaprim to benefit patients with cystic fibrosis who have lung infections.

The FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

The World Health Organization (WHO) released its first report on antibiotic resistance surveillance data.

Historically, postoperative pulmonary complications have been the most common serious adverse event following upper abdominal surgery, with incidence rates ranging from 10% to 50%.

Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.

More than $2 billion was invested in research and development relevant to the issue of antimicrobial resistance in 2016 alone.

Glenn Tillotson, PhD, FIDSA, discusses the costs of drug development.

A new article suggests that in order to combat antibiotic resistance in lower- and middle-income countries, particular attention needs to be paid to emerging One Health challenges.

A new study confirms the ribavirin steady-state serum levels that correspond to high rates of efficacy and low adverse events.

Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.

A recent study compares the effectiveness of a novel fidaxomicin therapy with vancomycin for the treatment of C. difficile.

Dr. Richard Vickers, explains how ridinilazole is unique in its spectrum of activity compared with other antibiotics that target C. diff and have been approved or are in development.

Rates of re-hospitalization and long-term health effects remain high among sepsis survivors, which is why researchers are outlining ways to help sepsis patients after hospital discharge.

The CDC releases first comprehensive reports on state progress made in the fight against antibiotic resistance since Congress’ investment in CDC’s Antibiotic Resistance Solutions Initiative.